A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.

Clinical trial NCT03770403 · COMPLETED

Trial details

NCT number: NCT03770403
Sponsor: argenx
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Generalized Myasthenia Gravis

Start date: 2019-03-01
Primary completion: 2022-06-23
Enrollment: 151

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.